NCT05960955View on ClinicalTrials.gov

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2027

Conditions

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Cadonilimab

IV infusion,Specified dose on specified days

DRUG

AK117

IV infusion,Specified dose on specified days

DRUG

Oxaliplatin

IV infusion,Specified dose on specified days

DRUG

Tegafur-gimeracil-oteracil potassium

Oral,Specified dose on specified days

DRUG

Docetaxel

IV infusion,Specified dose on specified days

DRUG

5-Fluorouracil

IV infusion,Specified dose on specified days

Trial Locations (1)

Unknown

RECRUITING

Tianjin Provincial Tumor Hospital, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT05960955 - Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter